Clinical Assessment and Management of Pathological Gambling

By Jon E. Grant, JD, MD, MPH and Suck Won Kim, MD | March 1, 2007

Dr Grant is associate professor of psychiatry at the University of Minnesota in Minneapolis. He reports that he is a consultant to Somaxon Pharmaceuticals and receives research grant support from Forest Pharmaceuticals, GlaxoSmithKline, and Somaxon Pharmaceuticals. Dr Kim is professor of psychiatry at the University of Minnesota in Minneapolis. He reports that he is a consultant to Somaxon Pharmaceuticals and BioTie Therapies.

Mood stabilizers. Because some pathological gamblers appear to have either co-occurring bipolar disorder or subsyndromal hypomania, the use of mood stabilizers has also been examined (see Table 2). There has been only one randomized placebo-controlled trial of a mood stabilizer in PG. In a double-blind placebo-controlled study of 40 subjects who were pathological gamblers with bipolar spectrum disorders (bipolar type II, bipolar not otherwise specified, or cyclothymia), sustained-release lithium(Drug information on lithium) carbonate (mean lithium blood level of 0.87 mEq/L) was shown to be superior to placebo in reducing PG symptoms during a 10-week treatment.²³

Psychosocial interventions
Controlled studies support the efficacy of cognitive and behavioral therapies for PG (Table 3). Cognitive therapy focuses on changing the patient's beliefs regarding his or her perceived control over randomly determined events. Randomized trials have demonstrated success with cognitive therapy.²⁴ Individual cognitive therapy has resulted in reduced gambling frequency and increased perceived self-control over gambling when compared with a wait-list control group. Cognitive therapy that includes relapse prevention has also produced improvements in gambling symptoms when compared with a wait- list group.


	Table 3 Controlled psychological treatment trials for PG
	Design			Outcome


	Stimulus control and in vivo exposure with relapse prevention; cognitive restructuring; combined treatment; or wait list25			At 12 months, 69% were abstinent or much reduced in the first group compared with 38% for cognitive restructuring or combined treatment

	Cognitive therapy plus relapse prevention compared with wait list³⁸			36% improved on 5 variables compared with 6% on wait list

	Cognitive therapy plus relapse prevention compared with wait list³⁹			32% improved on 4 variables compared with 7% on wait list

	Group cognitive therapy plus relapse prevention compared with wait list⁴⁰			65% no longer met PG criteria compared with 20% for wait-list group

	Manualized CBT in individual counseling; use of CBT workbook; or referral to Gamblers Anonymous²⁶			Individual CBT more effective than Gamblers Anonymous and use of workbook; at 12 months, groups did not differ in terms of abstinence rates

	Use of CBT workbook compared with use of a workbook plus a single in-depth interview²⁷			Both groups showed improvement at 6 months

	Use of CBT workbook; use of workbook plus motivational enhancement intervention via telephone; or wait list²⁸			74% with motivational enhancement improved according to Clinical Global Impression compared with 61% with use of workbook and 44% with wait list

	Aversion therapy compared with imaginal desensitization²⁹			Improvement in both groups over 12 months

	Aversion therapy; imaginal desensitization; in vivo desensitization; or imaginal relaxation³⁰			Improvements at 1-month and at 9-year follow-up with imaginal desensitization

	PG, pathological gambling; CBT, cognitive-behavioral therapy.

Cognitive-behavioral therapy (CBT) has been used to treat PG. One study compared 4 groups: (1) an individual stimulus control and in vivo exposure with response prevention; (2) group cognitive restructuring; (3) a combination of 1 and 2; and (4) a wait-list control.²⁵ At 12 months, the rates of abstinence or minimal gambling were higher with individual treatment (69%) than with both the cognitive restructuring and the combined treatment groups (38% abstinence or minimal gambling rate in each).

Based on CBT used in the treatment of substance use disorders and including relapse prevention strategies, an independent controlled trial of 231 subjects also demonstrated short-term improvement relative to a referral to Gamblers Anonymous (GA); at 12-month follow-up, however, abstinence rates did not differ between the 2 groups.²⁶

Brief interventions have demonstrated significant reductions in gambling at 6-month follow-up for gamblers assigned either to the use of a workbook (that included cognitive-behavioral and motivational enhancement techniques) or to the use of a workbook and an interview with a clinician.²⁷ A separate study assigned patients who were pathological gamblers to the use of a workbook, the use of a workbook and a motivational enhancement intervention over the telephone, or a wait list. Compared with the group who used the workbook alone, the group assigned to use motivational intervention and the workbook showed a reduction in gambling throughout the 2-year fol-low-up period.²⁸ Two studies that examined aversion therapy and imaginal desensitization in randomized designs found that both treatments resulted in improvement.^29,30

GA is perhaps the most popular and well-known treatment for PG, but few studies have systematically analyzed the outcomes of participation. Although controlled studies are lacking, most of the studies that examined treatment outcomes for patients who attended GA demonstrated the program's potential effectiveness, particularly when combined with professional therapy.³¹

CONCLUSION
PG has historically received relatively little attention from clinicians and researchers. Despite having prevalence rates similar to or greater than those of schizophrenia and bipolar disorder, there is much less research on PG that investigates treatment strategies. As a consequence, our understanding of effective and well-tolerated pharmacotherapies for PG lags behind that of other major neuropsychiatric disorders. Emerging data from controlled clinical trials, however, suggest that PG frequently responds to both pharmacological and psychosocial intervention.

The approaches reviewed in this article represent significant advances over the past several years—it is hoped that progress in the treatment of PG will continue to be made at this rate. More definitive treatment recommendations await the completion of additional large-scale controlled treatment studies and comparative investigations of trials of pharmacological agents. Advances in these areas hold the potential for significantly improving the lives of pathological gamblers and those directly or indirectly affected by their behavior.

Pages: 1 2 3

References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Text Revision. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
2. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999;89:1369-1376.
3. Argo T, Black DW. Clinical characteristics. In: Grant JE, Potenza MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Publishing; 2004.
4. Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two US national surveys. Am J Psychiatry. 2006;163:297-302.
5. Afifi TO, Cox BJ, Sareen J. Gambling-related problems are chronic and persist for the majority of individuals with a lifetime diagnosis of pathological gambling. Am J Psychiatry. 2006;163:1297.
6. Potenza MN, Kosten TR, Rounsaville BJ. Pathological gambling. JAMA. 2001;286:141-144.
7. Potenza MN, Steinberg MA, McLaughlin SD, et al. Gender-related differences in the characteristics of problem gamblers using a gambling helpline. Am J Psychiatry. 2001;158:1500-1505.
8. Grant JE, Kim SW. Demographic and clinical features of 131 adult pathological gamblers. J Clin Psychiatry. 2001;62:957-962.
9. Black DW, Moyer T. Clinical features and psychiatric comorbidity of subjects with pathological gambling behavior. Psychiatr Serv. 1998;49:1434-1439.
10. Bland RC, Newman SC, Orn H, Stebelsky G. Epidemiology of pathological gambling in Edmonton. Can J Psychiatry. 1993;38:108-112.
11. Linden RD, Pope HG Jr, Jonas JM. Pathological gambling and major affective disorder: preliminary findings. J Clin Psychiatry. 1986;47:201-203.
12. McCormick RA, Russo AM, Ramirez LF, Taber JI. Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry. 1984;141:215-218.
13. Grant JE, Kim SW. Comorbidity of impulse control disorders in pathological gamblers. Acta Psychiatr Scand. 2003;108:203-217.
14. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162:2184-2188.
15. Stinchfield R, Govoni R, Frisch GR. Screening and assessment instruments. In: Grant JE, Potenza MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Publishing; 2004.
16. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;59: 159-164.
17. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16:285-289.
18. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001; 49:914-921.
19. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001;21: 632-634.
20. Grant JE, Potenza MN, Hollander E, et al. A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303-312.
21. Potenza MN, Leung HC, Blumberg HP, et al. An fMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160:1990-1994.
22. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nature Neurosci. 2005;8:147-148.
23. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005; 162:137-145.
24. Hodgins DC, Petry NM. Cognitive and behavioral treatments. In: Grant JE, Potenza MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Publishing; 2004.
25. Echeburua E, Baez C, Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in psychological treatment of pathological gambling: long term outcome. Behav Cogn Psychother. 1996;24:51-72.
26. Petry NM, Ammerman Y, Bohl J, et al. Cognitive- behavioral therapy for pathological gamblers. J Consult Clin Psychol. 2006;74:555-567.
27. Dickerson M, Hinchy J, Legg England S. Minimal treatments and problem gamblers: a preliminary investigation. J Gambl Stud. 1990;6:87-102.
28. Hodgins DC, Currie SR, el-Guebaly N. Motivational enhancement and self-help treatments for problem gambling. J Consult Clin Psychol. 2001;69:50-57.
29. McConaghy N, Armstrong MS, Blaszczynski A, Allcock C. Controlled comparison of aversive therapy and imaginal desensitization in compulsive gambling. Br J Psychiatry. 1983;142:366-372.
30. McConaghy N, Blaszczynski A, Frankova A. Comparison of imaginal desensitization with other behavioral treatments of pathological gambling. A two- to nine-year follow-up. Br J Psychiatry. 1991;159:390-393.
31. Petry NM. Gamblers Anonymous and cognitive- behavioral therapies for pathological gamblers. J Gambl Stud. 2005,21:27-33.
32. Hollander E, Frenkel M, Decaria C, et al. Treatment of pathological gambling with clomipramine. Am J Psychiatry. 1992;149:710-711.
33. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47: 813-817.
34. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9-15.
35. Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507.
36. Grant JE,Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003; 18:243-249.
37. Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66:28-33.
38. Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol. 1997;65:727-732.
39. Ladouceur R, Sylvain C, Boutin C, et al. Cognitive treatment of pathological gambling. J Nerv Ment Dis. 2001;189:774-780.
40. Ladouceur R, Sylvain C, Boutin C, et al. Group therapy for pathological gamblers: a cognitive approach. Behav Res Ther. 2003;41:587-596.

FROM PHYSICIANS PRACTICE

Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND, May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.

VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri, May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?

Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC, May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.

Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson, May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.

Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker, May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.

Clinical Assessment and Management of Pathological Gambling

Join the Conversation